Details for Patent: 10,583,130
✉ Email this page to a colleague
Which drugs does patent 10,583,130 protect, and when does it expire?
Patent 10,583,130 protects ONGENTYS and is included in one NDA.
This patent has twenty-seven patent family members in fifteen countries.
Summary for Patent: 10,583,130
| Title: | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
| Abstract: | The present disclosure relates to compositions and pharmaceutical formulations comprising at least one active pharmaceutical ingredient chosen from nitrocatechol derivatives of formula I as defined herein and salts, esters, hydrates, solvates and derivatives thereof and methods of making said compositions and pharmaceutical formulations. |
| Inventor(s): | de Vasconcelos; Teofilo Cardoso (Sao Mamede do Coronado, PT), dos Santos Lima; Ricardo Jorge (Sao Mamede do Coronado, PT), de Campos Costa; Rui Cerdeira (Sao Mamede do Coronado, PT) |
| Assignee: | BIAL-PORTELA & CA, S.A. (S. Mamede do Coronado, PT) |
| Application Number: | 16/050,602 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Recent additions to Drugs Protected by US Patent 10,583,130
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | ONGENTYS | opicapone | CAPSULE | 212489 | Apr 24, 2020 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-3869 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,583,130
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-001 | Apr 24, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
| Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-002 | Apr 24, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,583,130
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010231961 | ⤷ Try a Trial | |||
| Brazil | PI1014865 | ⤷ Try a Trial | |||
| Canada | 2757411 | ⤷ Try a Trial | |||
| China | 102448444 | ⤷ Try a Trial | |||
| China | 105878242 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
